Hatch/Waxman Reform Bill Needed Despite FDA Rule – McCain, Schumer
This article was originally published in The Tan Sheet
Executive Summary
Legislation to reform the generic drug approval process will still be needed following issuance of FDA's final rule, Sens. John McCain (R-Ariz.) and Charles Schumer (D-N.Y.) said
You may also be interested in...
Senate Health Committee Plans To Codify FDA Generic Drug Proposal
The Senate Health & Education Committee plans to codify FDA's Hatch/Waxman reform proposal after the final rule is issued
30-Month Stay Proposal Would Delay Generics, Should Be Withdrawn, GPhA Says
FDA's proposed rule on 30-month stays would discourage timely suits by brand-name firms and should not be implemented, according to the Generic Pharmaceutical Association
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC